Vaccinex AI Stock Analysis
Want to see VCNX full AI Analyst Report?
Vaccinex (VCNX) AI Stock Analysis
Vaccinex
(Other OTC:VCNX)
The overall score of 48.5 reflects a high-risk, speculative biotechnology company. The most significant factor is the extremely weak balance sheet with negative equity and high leverage, which poses a going-concern risk. Partially offsetting this are improving operational trends, including strong revenue growth and narrowing losses, and moderately bullish short-term technical momentum. However, the company remains unprofitable with negative cash flows, and the stock's longer-term technical trend is bearish. The score is constrained by the precarious financial state.
Vaccinex (VCNX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.41M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,535
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 1.83
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 25
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Vaccinex Business Overview & Revenue Model
Company Description
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate trea...
How the Company Makes Money
Vaccinex has historically not had meaningful recurring revenue from product sales because it has not broadly commercialized an approved therapeutic product. As a clinical-stage biotech, its funding and any revenue have typically been driven by (1) co...
Vaccinex Financial Statement Overview
Summary
Financial performance is weak but improving. Revenue grew 249% to $2.1M with 98% gross margins, and net losses narrowed to -$5.3M. However, the balance sheet is critically distressed with -$7.6M equity and debt exceeding assets, while cash flow remains negative. The overall financial health is fragile and high-risk.
Income Statement
30NegativeBalance Sheet
10Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 601.00K | 2.10M | 601.00K | 570.00K | 100.00K | 900.00K |
| Gross Profit | 574.00K | 2.06M | 601.00K | 570.00K | 68.00K | 731.00K |
| EBITDA | -18.51M | -5.20M | -18.54M | -19.75M | -19.61M | -21.40M |
| Net Income | -18.63M | -5.26M | -18.63M | -20.25M | -19.72M | -22.38M |
Balance Sheet | ||||||
| Total Assets | 2.60M | 1.80M | 2.60M | 3.63M | 7.98M | 9.84M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11M | 140.00K | 1.11M | 1.53M | 6.39M | 8.59M |
| Total Debt | 25.00K | 5.52M | 25.00K | 247.00K | 485.00K | 390.00K |
| Total Liabilities | 5.08M | 9.39M | 5.08M | 5.94M | 2.78M | 2.43M |
| Stockholders Equity | -2.49M | -7.59M | -2.49M | -2.31M | 5.19M | 7.41M |
Cash Flow | ||||||
| Free Cash Flow | -16.21M | -6.46M | -16.21M | -17.30M | -19.17M | -25.33M |
| Operating Cash Flow | -16.19M | -6.45M | -16.19M | -17.23M | -19.07M | -25.30M |
| Investing Cash Flow | -22.00K | -9,000 | -22.00K | -67.00K | -99.00K | -32.00K |
| Financing Cash Flow | 15.78M | 5.49M | 15.78M | 12.45M | 16.98M | 23.32M |
Vaccinex Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Negative. The current price of 0.97 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.96, and below the 200-day MA of 1.01, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 77.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VCNX.
Vaccinex Risk Analysis
Vaccinex disclosed 49 risk factors in its most recent earnings report. Vaccinex reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVaccinex Peers Comparison
Overall Rating
VCNX48.5Neutral
AZTR44Neutral
REVB41Neutral
GTBP40Underperform
TOVX31Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $2.41M | -0.49 | 104.38% | ― | ― | ― | |
| 44Neutral | $3.22M | -0.08 | -191.57% | ― | ― | 87.93% | |
| 41Neutral | $2.52M | -0.09 | -124.23% | ― | ― | 94.95% | |
| 40Underperform | $6.80M | -0.02 | -548.33% | ― | ― | 60.31% | |
| 31Underperform | $5.87M | -0.48 | -64.99% | ― | ― | 95.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VCNX | Vaccinex | 0.97 | 0.29 | 43.24% | |
| TOVX | Theriva Biologics, Inc. | 0.12 | -0.11 | -47.83% | |
| GTBP | Gt Biopharma, Inc. | 2.96 | -16.07 | -84.45% | |
| REVB | Revelation Biosciences Inc. | 3.50 | -20.31 | -85.30% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.06 | -85.07% | |
| AZTR | Azitra Inc | 0.52 | -2.71 | -84.03% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
